134-47-4 Usage
Description
6,6'-Ureylene-bis(1-naphthol-3-sulfonic acid) is an organic compound with a unique chemical structure that features a central carbonyl group connecting two naphthol-3-sulfonic acid moieties through their 6,6' positions. 6,6'-Ureylene-bis(1-naphthol-3-sulfonic acid) is known for its pharmacological properties and potential applications in various industries.
Uses
Used in Pharmaceutical Industry:
6,6'-Ureylene-bis(1-naphthol-3-sulfonic acid) is used as a pharmacologically active compound for its selective nonbisphosphonate inhibition of human geranylgeranyl diphosphate synthase. This inhibition plays a crucial role in the regulation of cellular processes and may have therapeutic implications for various diseases.
Additionally, 6,6'-Ureylene-bis(1-naphthol-3-sulfonic acid) is used as an inhibitor of shikimate dehydrogenase and shikimate kinase in the shikimate pathway of Helicobacter pylori. This application is significant for the development of novel treatments against bacterial infections, particularly those caused by H. pylori, which is a common cause of gastric ulcers and other gastrointestinal issues.
Check Digit Verification of cas no
The CAS Registry Mumber 134-47-4 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 1,3 and 4 respectively; the second part has 2 digits, 4 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 134-47:
(5*1)+(4*3)+(3*4)+(2*4)+(1*7)=44
44 % 10 = 4
So 134-47-4 is a valid CAS Registry Number.
134-47-4Relevant articles and documents
Small molecule inhibitors of histone arginine methyltransferases: Homology modeling, molecular docking, binding mode analysis, and biological evaluations
Ragno, Rino,Simeoni, Silvia,Castellano, Sabrina,Vicidomini, Caterina,Mai, Antonello,Caroli, Antonella,Tramontano, Anna,Bonaccini, Claudia,Trojer, Patrick,Bauer, Ingo,Brosch, Gerald,Sbardella, Gianluca
, p. 1241 - 1253 (2007)
The screening of the inhibition capabilities of dye-like small molecules from a focused library against both human PRMT1 and Aspergillus nidulans RmtA is reported as well as molecular modeling studies (homology modeling, molecular docking, and 3-D QSAR) o